tradingkey.logo

cbdMD Inc

YCBD
查看详细走势图
1.490USD
-0.440-22.80%
收盘 12/19, 16:00美东报价延迟15分钟
13.27M总市值
亏损市盈率 TTM

cbdMD Inc

1.490
-0.440-22.80%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-22.80%

5天

+24.17%

1月

+195.81%

6月

+81.71%

今年开始到现在

-50.33%

1年

-48.26%

查看详细走势图

TradingKey cbdMD Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

cbdMD Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名109/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价2.00。中期看,股价处于上升通道。近一个月,市场表现很强,基本面评分较高,但很强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

cbdMD Inc评分

相关信息

行业排名
109 / 158
全市场排名
308 / 4582
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 1 位分析师
买入
评级
2.000
目标均价
+213.19%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

cbdMD Inc亮点

亮点风险
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
业绩增长期
公司处于发展阶段,最新年度总收入19.19M美元
估值低估
公司最新PE估值-1.39,处于3年历史低位
机构加仓
最新机构持股502.25K股,环比增加27.27%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00
活跃度增加
近期活跃度增加,过去20天平均换手率-0.27

cbdMD Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

cbdMD Inc简介

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
公司代码YCBD
公司cbdMD Inc
CEOKennedy (T. Ronan)
网址https://www.cbdmd.com/

常见问题

cbdMD Inc(YCBD)的当前股价是多少?

cbdMD Inc(YCBD)的当前股价是 1.490。

cbdMD Inc的股票代码是什么?

cbdMD Inc的股票代码是YCBD。

cbdMD Inc股票的52周最高点是多少?

cbdMD Inc股票的52周最高点是6.538。

cbdMD Inc股票的52周最低点是多少?

cbdMD Inc股票的52周最低点是0.470。

cbdMD Inc的市值是多少?

cbdMD Inc的市值是13.27M。

cbdMD Inc的净利润是多少?

cbdMD Inc的净利润为-7.70M。

现在cbdMD Inc(YCBD)的股票是买入、持有还是卖出?

根据分析师评级,cbdMD Inc(YCBD)的总体评级为买入,目标价格为2.000。

cbdMD Inc(YCBD)股票的每股收益(EPS TTM)是多少

cbdMD Inc(YCBD)股票的每股收益(EPS TTM)是-1.138。
KeyAI